Consequently, targeting of H3R with antagonist/inverse agonist may have therapeutic applications in CNS-related disorders, such as depression, schizophrenia, PD, and AD (Esbenshade et al., 2008; Gemkow et al., 2009; Chazot, 2010; Raddatz et al., 2010; Lin et al., 2011; Ghasemi and Tavakoli, 2012) as well as in inflammatory and gastrointestinal diseases (Vuyyuru et al., 1995; Ceras et al., 2012). Here, HRH3 is linked to depressive symptom measurement.